SCHEMBL176911

SCHEMBL176911

CC(C)c1n[nH]c2cc(OCCN)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 3/20 0.39
CDC7 O00311 1/20 0.39
DAPK3 O43293 1/20 0.39
DYRK3 O43781 1/20 0.39
ROCK2 O75116 1/20 0.39
RPS6KA5 O75582 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PRKCG P05129 1/20 0.39
CDK1 P06493 1/20 0.39
PIM1 P11309 1/20 0.39
PHKG2 P15735 1/20 0.39
PRKACA P17612 1/20 0.39
CDK2 P24941 1/20 0.39
MARK3 P27448 1/20 0.39
MAPK1 P28482 1/20 0.39
AKT1 P31749 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
CDK8 P49336 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isopropyl Alcohol SCHEMBL177402 0.96 DYRK1A (0.40) DYRK1ACDC7DAPK3DYRK3ROCK2
SCHEMBL17229809 0.79 KDM4E (0.45) DYRK1ADYRK3CDK1CDK2CSNK1D
SCHEMBL177401 0.77 AAK1 (0.41) DYRK1ACLK2MAOA
SCHEMBL2304023 0.74 CDK2 (0.36) DYRK1ACDC7DAPK3DYRK3ROCK2
SCHEMBL1798750 0.72 MAOA (0.46) DYRK1AALKHTR1AHTR1BHTR1D
SCHEMBL11963297 0.71 CDC7 (0.50) CDC7ROCK2MAP4K4PIM1PRKACA
SCHEMBL12090196 0.71 ITK (0.47) MAPK1AURKBITK
SCHEMBL18806213 0.71 KIF11 (0.47) DYRK1ADAPK3MAP4K4CLK2GSK3A
SCHEMBL27838922 0.70 GABRA1 (0.43) HTR1BHTR1D
SCHEMBL24991934 0.70 KIF11 (0.44) GSK3BAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
EP-2345644-A1 INDAZOLE COMPOUND Asahi Kasei Pharma Corporation (JP) 2011-07-20 EP disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
WO-2010041569-A1 INDAZOLE COMPOUND 旭化成ファーマ株式会社 (JP) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160256-A1 INDAZOLE COMPOUNDS GPR119, ADRB1, ADRA1A DYRK1A 2467/4885CDC7 3144/4885DAPK3 3427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.